Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8013304 | 0.95 | PSMB5 (0.59) | GRIA1PSMB5GPR132ITGB1ITGA5 | |
| SCHEMBL21623659 | 0.92 | PSMB5 (0.62) | PSMB5MMEGPR132CA2ACE | |
| SCHEMBL9554481 | 0.92 | PSMB5 (0.62) | PSMB5MMEGPR132CA2ACE | |
| SCHEMBL12015221 | 0.85 | PSMB5 (0.51) | GRIA1PSMB5GPR132ITGB1ITGA5 | |
| SCHEMBL7959534 | 0.84 | PSMB5 (0.53) | GRIA1PSMB5GPR132ITGB1ITGA5 | |
| SCHEMBL12004867 | 0.84 | GRIA1 (0.56) | GRIA1PSMB5USP30 | |
| SCHEMBL3938112 | 0.84 | GRIA1 (0.56) | GRIA1PSMB5USP30 | |
| SCHEMBL19899634 | 0.84 | FPR2 (0.56) | PSMB5GPR132CA1CA2ITGB1 | |
| SCHEMBL19899636 | 0.84 | FPR2 (0.56) | PSMB5GPR132CA1CA2ITGB1 | |
| SCHEMBL8513905 | 0.83 | PSMB5 (0.58) | PSMB5GPR132CA1CA2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102807600-A | Amino acid modified spinacin derivative and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-12-05 | — | — | CN | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| WO-2011052715-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | 第一三共株式会社 (JP) | 2011-05-05 | — | — | WO | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | GRIA1 4220/4885PSMB5 872/4885MME 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.